Corient Private Wealth LLC Trims Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Corient Private Wealth LLC lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 16.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 22,884 shares of the biopharmaceutical company's stock after selling 4,349 shares during the quarter. Corient Private Wealth LLC's holdings in Regeneron Pharmaceuticals were worth $16,302,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Amundi boosted its stake in Regeneron Pharmaceuticals by 45.8% during the fourth quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company's stock worth $1,138,074,000 after acquiring an additional 487,489 shares in the last quarter. Proficio Capital Partners LLC boosted its stake in Regeneron Pharmaceuticals by 92,865.3% during the fourth quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company's stock worth $156,284,000 after acquiring an additional 219,162 shares in the last quarter. Worldquant Millennium Advisors LLC bought a new stake in Regeneron Pharmaceuticals during the third quarter worth about $127,489,000. KBC Group NV boosted its stake in Regeneron Pharmaceuticals by 296.7% during the fourth quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company's stock worth $97,338,000 after acquiring an additional 102,198 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in Regeneron Pharmaceuticals during the fourth quarter worth about $65,180,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Remove Ads

Regeneron Pharmaceuticals Stock Performance

REGN stock traded down $4.14 during midday trading on Friday, reaching $658.48. 1,869,108 shares of the company's stock traded hands, compared to its average volume of 634,475. Regeneron Pharmaceuticals, Inc. has a 52-week low of $642.00 and a 52-week high of $1,211.20. The stock has a market cap of $71.99 billion, a P/E ratio of 17.20, a PEG ratio of 2.34 and a beta of 0.27. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The stock's 50-day moving average is $689.43 and its 200 day moving average is $815.71.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.79 billion during the quarter, compared to analysts' expectations of $3.76 billion. During the same period in the prior year, the company earned $11.86 earnings per share. The firm's revenue was up 10.3% on a year-over-year basis. As a group, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were paid a $0.88 dividend. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.53%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 2.30%.

Analyst Upgrades and Downgrades

Several research firms recently commented on REGN. TD Cowen dropped their price objective on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating on the stock in a research note on Tuesday, February 4th. Canaccord Genuity Group downgraded shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, December 17th. Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, February 5th. Canaccord Genuity Group assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They issued a "hold" rating and a $165.00 target price on the stock. Finally, Robert W. Baird dropped their target price on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating on the stock in a research note on Wednesday, February 5th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.